1. Combinatorial drug discovery in nanoliter droplets
- Author
-
Prianca Tawde, Anthony Kulesa, Jared Kehe, Paul C. Blainey, and Juan E. Hurtado
- Subjects
0301 basic medicine ,medicine.drug_class ,Phenotypic screening ,High-throughput screening ,Antibiotics ,Drug Evaluation, Preclinical ,Microbial Sensitivity Tests ,Computational biology ,Pharmacology ,Biology ,01 natural sciences ,Chemical library ,Small Molecule Libraries ,03 medical and health sciences ,chemistry.chemical_compound ,Vancomycin ,Lab-On-A-Chip Devices ,Drug Discovery ,Escherichia coli ,medicine ,Combinatorial Chemistry Techniques ,Nanotechnology ,Multidisciplinary ,010405 organic chemistry ,Drug discovery ,Drug Synergism ,Biological Sciences ,Microarray Analysis ,Chemical space ,Anti-Bacterial Agents ,Erythromycin ,High-Throughput Screening Assays ,0104 chemical sciences ,030104 developmental biology ,Synergy ,chemistry ,Infectious disease (medical specialty) ,Pseudomonas aeruginosa ,Novobiocin - Abstract
Combinatorial drug treatment strategies perturb biological networks synergistically to achieve therapeutic effects and represent major opportunities to develop advanced treatments across a variety of human disease areas. However, the discovery of new combinatorial treatments is challenged by the sheer scale of combinatorial chemical space. Here we report a high-throughput system for nanoliter-scale phenotypic screening that stabilizes a chemical library in nanoliter droplet emulsions and automates the formulation of chemical combinationsen massusing parallel droplet processing. We apply this system to predict synergy between more than 4,000 investigational and approved drugs and a panel of 10 antibiotics againstE. coli, a model Gram-negative pathogen. We found a range of drugs not previously indicated for infectious disease that synergize with antibiotics. Our validated hits include drugs that synergize with the antibiotics vancomycin, erythromycin, and novobiocin, which are used against Gram-positive bacteria but are not effective by themselves to resolve Gram-negative infections.
- Published
- 2018